Your browser doesn't support javascript.
loading
Trajectory for the Regulatory Approval of a Combination of Pertuzumab Plus Trastuzumab for Pre-treated HER2-positive Metastatic Colorectal Cancer Using Real-world Data.
Sakamoto, Yasutoshi; Bando, Hideaki; Nakamura, Yoshiaki; Hasegawa, Hiromi; Kuwaki, Takako; Okamoto, Wataru; Taniguchi, Hiroya; Aoyagi, Yoshihiro; Miki, Izumi; Uchigata, Hiroshi; Kuramoto, Naomi; Fuse, Nozomu; Yoshino, Takayuki; Ohtsu, Atsushi.
Afiliação
  • Sakamoto Y; Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Bando H; Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Ce
  • Nakamura Y; Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Ce
  • Hasegawa H; Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Kuwaki T; Research Audit Section, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Okamoto W; Cancer Treatment Center, Hiroshima University Hospital, Hiroshima, Japan.
  • Taniguchi H; Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Aichi, Japan.
  • Aoyagi Y; Information Technology Management Section, Clinical Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Miki I; Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Uchigata H; Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Kuramoto N; Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Fuse N; Clinical Research Planning Division, Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Yoshino T; Translational Research Support Office, Division of Drug and Diagnostic Development Promotion, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Ce
  • Ohtsu A; National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Clin Colorectal Cancer ; 22(1): 45-52, 2023 03.
Article em En | MEDLINE | ID: mdl-36376197

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias Colorretais Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Clin Colorectal Cancer Assunto da revista: GASTROENTEROLOGIA / NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Neoplasias Colorretais Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Clin Colorectal Cancer Assunto da revista: GASTROENTEROLOGIA / NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão